The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Plasma-derived Factor VIII Market Research Report 2025
Synopsis
RECOMBINATE is recombinant Factor VIII, a clotting factor that is deficient in people with hemophilia A.
The global Plasma-derived Factor VIII market was valued at US$ 8761 million in 2023 and is anticipated to reach US$ 12950 million by 2030, witnessing a CAGR of 5.7% during the forecast period 2024-2030.
The market growth can be attributed to several factors. Firstly, the increasing prevalence of hemophilia A and the rising awareness about the importance of early diagnosis and treatment have led to a growing demand for Factor VIII products. The availability of plasma-derived Factor VIII provides an effective treatment option for patients who require clotting factor replacement therapy. Secondly, advancements in manufacturing techniques and purification processes have improved the safety and efficacy of plasma-derived Factor VIII products. Stringent regulatory standards and guidelines for plasma collection and fractionation have instilled confidence among healthcare providers and patients regarding the safety of these products.
This report aims to provide a comprehensive presentation of the global market for Plasma-derived Factor VIII, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Plasma-derived Factor VIII.
Report Scope
The Plasma-derived Factor VIII market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Plasma-derived Factor VIII market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Plasma-derived Factor VIII manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Takeda
Octapharma
CSL
Grifols
Greencross
Kedrion
BPL
Hualan Bio
RAAS
Segment by Type
200IU
250IU
Segment by Application
Hospital
Pharmacy
Consumption by Region
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Plasma-derived Factor VIII manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Plasma-derived Factor VIII in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
RECOMBINATE is recombinant Factor VIII, a clotting factor that is deficient in people with hemophilia A.
The global Plasma-derived Factor VIII market was valued at US$ 8761 million in 2023 and is anticipated to reach US$ 12950 million by 2030, witnessing a CAGR of 5.7% during the forecast period 2024-2030.
The market growth can be attributed to several factors. Firstly, the increasing prevalence of hemophilia A and the rising awareness about the importance of early diagnosis and treatment have led to a growing demand for Factor VIII products. The availability of plasma-derived Factor VIII provides an effective treatment option for patients who require clotting factor replacement therapy. Secondly, advancements in manufacturing techniques and purification processes have improved the safety and efficacy of plasma-derived Factor VIII products. Stringent regulatory standards and guidelines for plasma collection and fractionation have instilled confidence among healthcare providers and patients regarding the safety of these products.
This report aims to provide a comprehensive presentation of the global market for Plasma-derived Factor VIII, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Plasma-derived Factor VIII.
Report Scope
The Plasma-derived Factor VIII market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Plasma-derived Factor VIII market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Plasma-derived Factor VIII manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Takeda
Octapharma
CSL
Grifols
Greencross
Kedrion
BPL
Hualan Bio
RAAS
Segment by Type
200IU
250IU
Segment by Application
Hospital
Pharmacy
Consumption by Region
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Plasma-derived Factor VIII manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Plasma-derived Factor VIII in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Plasma-derived Factor VIII Market Overview
1.1 Product Overview and Scope of Plasma-derived Factor VIII
1.2 Plasma-derived Factor VIII Segment by Type
1.2.1 Global Plasma-derived Factor VIII Market Value Comparison by Type (2024-2030)
1.2.2 200IU
1.2.3 250IU
1.3 Plasma-derived Factor VIII Segment by Application
1.3.1 Global Plasma-derived Factor VIII Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Pharmacy
1.4 Global Plasma-derived Factor VIII Market Size Estimates and Forecasts
1.4.1 Global Plasma-derived Factor VIII Revenue 2019-2030
1.4.2 Global Plasma-derived Factor VIII Sales 2019-2030
1.4.3 Global Plasma-derived Factor VIII Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Plasma-derived Factor VIII Market Competition by Manufacturers
2.1 Global Plasma-derived Factor VIII Sales Market Share by Manufacturers (2019-2024)
2.2 Global Plasma-derived Factor VIII Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Plasma-derived Factor VIII Average Price by Manufacturers (2019-2024)
2.4 Global Plasma-derived Factor VIII Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Plasma-derived Factor VIII, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Plasma-derived Factor VIII, Product Type & Application
2.7 Plasma-derived Factor VIII Market Competitive Situation and Trends
2.7.1 Plasma-derived Factor VIII Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Plasma-derived Factor VIII Players Market Share by Revenue
2.7.3 Global Plasma-derived Factor VIII Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Plasma-derived Factor VIII Retrospective Market Scenario by Region
3.1 Global Plasma-derived Factor VIII Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Plasma-derived Factor VIII Global Plasma-derived Factor VIII Sales by Region: 2019-2030
3.2.1 Global Plasma-derived Factor VIII Sales by Region: 2019-2024
3.2.2 Global Plasma-derived Factor VIII Sales by Region: 2025-2030
3.3 Global Plasma-derived Factor VIII Global Plasma-derived Factor VIII Revenue by Region: 2019-2030
3.3.1 Global Plasma-derived Factor VIII Revenue by Region: 2019-2024
3.3.2 Global Plasma-derived Factor VIII Revenue by Region: 2025-2030
3.4 North America Plasma-derived Factor VIII Market Facts & Figures by Country
3.4.1 North America Plasma-derived Factor VIII Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Plasma-derived Factor VIII Sales by Country (2019-2030)
3.4.3 North America Plasma-derived Factor VIII Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.4.6 Mexico
3.5 Europe Plasma-derived Factor VIII Market Facts & Figures by Country
3.5.1 Europe Plasma-derived Factor VIII Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Plasma-derived Factor VIII Sales by Country (2019-2030)
3.5.3 Europe Plasma-derived Factor VIII Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 UK
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Plasma-derived Factor VIII Market Facts & Figures by Country
3.6.1 Asia Pacific Plasma-derived Factor VIII Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Plasma-derived Factor VIII Sales by Country (2019-2030)
3.6.3 Asia Pacific Plasma-derived Factor VIII Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Plasma-derived Factor VIII Market Facts & Figures by Country
3.7.1 Latin America Plasma-derived Factor VIII Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Plasma-derived Factor VIII Sales by Country (2019-2030)
3.7.3 Latin America Plasma-derived Factor VIII Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Plasma-derived Factor VIII Market Facts & Figures by Country
3.8.1 Middle East and Africa Plasma-derived Factor VIII Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Plasma-derived Factor VIII Sales by Country (2019-2030)
3.8.3 Middle East and Africa Plasma-derived Factor VIII Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Plasma-derived Factor VIII Sales by Type (2019-2030)
4.1.1 Global Plasma-derived Factor VIII Sales by Type (2019-2024)
4.1.2 Global Plasma-derived Factor VIII Sales by Type (2025-2030)
4.1.3 Global Plasma-derived Factor VIII Sales Market Share by Type (2019-2030)
4.2 Global Plasma-derived Factor VIII Revenue by Type (2019-2030)
4.2.1 Global Plasma-derived Factor VIII Revenue by Type (2019-2024)
4.2.2 Global Plasma-derived Factor VIII Revenue by Type (2025-2030)
4.2.3 Global Plasma-derived Factor VIII Revenue Market Share by Type (2019-2030)
4.3 Global Plasma-derived Factor VIII Price by Type (2019-2030)
5 Segment by Application
5.1 Global Plasma-derived Factor VIII Sales by Application (2019-2030)
5.1.1 Global Plasma-derived Factor VIII Sales by Application (2019-2024)
5.1.2 Global Plasma-derived Factor VIII Sales by Application (2025-2030)
5.1.3 Global Plasma-derived Factor VIII Sales Market Share by Application (2019-2030)
5.2 Global Plasma-derived Factor VIII Revenue by Application (2019-2030)
5.2.1 Global Plasma-derived Factor VIII Revenue by Application (2019-2024)
5.2.2 Global Plasma-derived Factor VIII Revenue by Application (2025-2030)
5.2.3 Global Plasma-derived Factor VIII Revenue Market Share by Application (2019-2030)
5.3 Global Plasma-derived Factor VIII Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Takeda
6.1.1 Takeda Corporation Information
6.1.2 Takeda Description and Business Overview
6.1.3 Takeda Plasma-derived Factor VIII Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Takeda Plasma-derived Factor VIII Product Portfolio
6.1.5 Takeda Recent Developments/Updates
6.2 Octapharma
6.2.1 Octapharma Corporation Information
6.2.2 Octapharma Description and Business Overview
6.2.3 Octapharma Plasma-derived Factor VIII Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Octapharma Plasma-derived Factor VIII Product Portfolio
6.2.5 Octapharma Recent Developments/Updates
6.3 CSL
6.3.1 CSL Corporation Information
6.3.2 CSL Description and Business Overview
6.3.3 CSL Plasma-derived Factor VIII Sales, Revenue and Gross Margin (2019-2024)
6.3.4 CSL Plasma-derived Factor VIII Product Portfolio
6.3.5 CSL Recent Developments/Updates
6.4 Grifols
6.4.1 Grifols Corporation Information
6.4.2 Grifols Description and Business Overview
6.4.3 Grifols Plasma-derived Factor VIII Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Grifols Plasma-derived Factor VIII Product Portfolio
6.4.5 Grifols Recent Developments/Updates
6.5 Greencross
6.5.1 Greencross Corporation Information
6.5.2 Greencross Description and Business Overview
6.5.3 Greencross Plasma-derived Factor VIII Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Greencross Plasma-derived Factor VIII Product Portfolio
6.5.5 Greencross Recent Developments/Updates
6.6 Kedrion
6.6.1 Kedrion Corporation Information
6.6.2 Kedrion Description and Business Overview
6.6.3 Kedrion Plasma-derived Factor VIII Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Kedrion Plasma-derived Factor VIII Product Portfolio
6.6.5 Kedrion Recent Developments/Updates
6.7 BPL
6.6.1 BPL Corporation Information
6.6.2 BPL Description and Business Overview
6.6.3 BPL Plasma-derived Factor VIII Sales, Revenue and Gross Margin (2019-2024)
6.4.4 BPL Plasma-derived Factor VIII Product Portfolio
6.7.5 BPL Recent Developments/Updates
6.8 Hualan Bio
6.8.1 Hualan Bio Corporation Information
6.8.2 Hualan Bio Description and Business Overview
6.8.3 Hualan Bio Plasma-derived Factor VIII Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Hualan Bio Plasma-derived Factor VIII Product Portfolio
6.8.5 Hualan Bio Recent Developments/Updates
6.9 RAAS
6.9.1 RAAS Corporation Information
6.9.2 RAAS Description and Business Overview
6.9.3 RAAS Plasma-derived Factor VIII Sales, Revenue and Gross Margin (2019-2024)
6.9.4 RAAS Plasma-derived Factor VIII Product Portfolio
6.9.5 RAAS Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Plasma-derived Factor VIII Industry Chain Analysis
7.2 Plasma-derived Factor VIII Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Plasma-derived Factor VIII Production Mode & Process
7.4 Plasma-derived Factor VIII Sales and Marketing
7.4.1 Plasma-derived Factor VIII Sales Channels
7.4.2 Plasma-derived Factor VIII Distributors
7.5 Plasma-derived Factor VIII Customers
8 Plasma-derived Factor VIII Market Dynamics
8.1 Plasma-derived Factor VIII Industry Trends
8.2 Plasma-derived Factor VIII Market Drivers
8.3 Plasma-derived Factor VIII Market Challenges
8.4 Plasma-derived Factor VIII Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
